Oral Antidiabetic Drugs Market Growth, Size, Trends Analysis - By Disease Type, By Drug Class, By Medication Type, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Oral Antidiabetic Drugs Market Introduction and Overview

According to SPER market research, ‘Global Oral Antidiabetic Drugs Market Size- By Disease Type, By Drug Class, By Medication Type, By Distribution Channel – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ states that the Global Oral Antidiabetic Drugs Market is predicted to reach 70.63 billion by 2034 with a CAGR of 4.13%.

People with diabetes, particularly those with type 2, can better manage and control their blood glucose levels by taking oral antidiabetic medications. These drugs can increase the body’s sensitivity to insulin, decrease the liver’s production of glucose, delay the intestinal absorption of carbohydrates, or increase the amount of insulin secreted by the pancreas. They are usually suggested when dietary and physical activity modifications are insufficient to sustain optimal blood sugar regulation.

Restraints:

When the patents on important medications expire, generics become available, increasing price competition and decreasing profit margins. Long approval procedures and strict regulatory requirements cause delays in the launch of new treatments. Patient acceptance and doctor prescriptions may be restricted by adverse effects and safety issues, such as cardiovascular or renal hazards. High treatment costs and a lack of adequate healthcare infrastructure limit access to cutting-edge drugs in low- and middle-income areas.

Scope of the report:

Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034

Segments covered By

Disease Type, By Drug Class, By Medication Type, By Distribution Channel

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered

Astellas Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly & Company, Glenmark Pharmaceuticals, Johnson & Johnson (Janssen Pharmaceuticals), Merck, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda Pharmaceuticals.

Global Oral Antidiabetic Drugs Market Segmentation:

By Disease Type: Based on the Disease Type, Global Oral Antidiabetic Drugs Market is segmented as; Type 2 diabetes, Type 1 diabetes.

By Drug Class: Based on the Drug Class, Global Oral Antidiabetic Drugs Market is segmented as; Biguanides, Dipeptidyl peptidase - 4 (DPP-4) inhibitors, Sodium-glucose transport protein-2 (SGLT-2) inhibitors, Sulfonylureas, Thiazolidinediones, Meglitinides, Alpha-glucosidase inhibitors.

By Medication Type: Based on the Medication Type, Global Oral Antidiabetic Drugs Market is segmented as; Branded, Generic.

By Distribution Channel: Based on the Distribution Channel, Global Oral Antidiabetic Drugs Market is segmented as; Hospital pharmacies, Retail pharmacies, Online pharmacies.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa. Show more